OncoMatch/Clinical Trials/NCT06593431
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Is NCT06593431 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for pancreas cancer.
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Kidney function
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Liver function
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify